[Form 4] VIAVI SOLUTIONS INC. Insider Trading Activity
Kevin Christopher Siebert, SVP General Counsel & Secretary of VIAVI Solutions Inc. (VIAV), reported a sale of 9,927 shares of the issuer's common stock on 09/25/2025. The sale was made pursuant to a Rule 10b5-1 stock trading plan dated September 10, 2024, and was executed in multiple trades at prices ranging from $12.08 to $12.27, with a weighted average sale price of $12.17. Following the reported transaction, the reporting person beneficially owned 84,598 shares. The Form 4 was signed by attorney-in-fact Donna T. Rossi.
Kevin Christopher Siebert, Senior Vice President, General Counsel e Segretario di VIAVI Solutions Inc. (VIAV), ha riportato una vendita di 9.927 azioni ordinarie dell'emittente in data 25/09/2025. La vendita è stata effettuata conformemente a un piano di negoziazione azionaria Rule 10b5-1 datato 10 settembre 2024 ed è stata eseguita in più operazioni a prezzi compresi tra $12,08 e $12,27, con un prezzo medio ponderato di vendita di $12,17. A seguito della transazione riportata, la persona che presenta il rapporto deteneva 84.598 azioni in modo benefit. Il Form 4 è stato firmato dall'avvocato-in-fatto Donna T. Rossi.
Kevin Christopher Siebert, vicepresidente senior y asesor jurídico general y Secretario de VIAVI Solutions Inc. (VIAV), informó la venta de 9.927 acciones ordinarias del emisor en 25/09/2025. La venta se realizó conforme a un plan de negociación de acciones Rule 10b5-1 con fecha del 10 de septiembre de 2024, y se ejecutó en múltiples operaciones a precios que oscilaron entre $12,08 y $12,27, con un precio medio ponderado de venta de $12,17. Tras la transacción reportada, la persona reportante poseía beneficiosamente 84.598 acciones. El Formulario 4 fue firmado por la apoderada Donna T. Rossi.
Kevin Christopher Siebert은 VIAVI Solutions Inc. (VIAV)의 SVP 일반 counsel 겸 비서로서 발행 회사의 보통주 9,927주를 2025-09-25에 매각했다고 보고했습니다. 매각은 Rule 10b5-1 주식 거래 계획에 따라 2024년 9월 10일에 date되었으며, $12.08에서 $12.27 사이의 가격으로 여러 차례 거래되었고, 가중평균 매각가 $12.17입니다. 보고된 거래 이후 보고서는 84,598주의 보유를 보고합니다. Form 4는 대리인 Donna T. Rossi가 서명했습니다.
Kevin Christopher Siebert, vice-président exécutif, conseil général et secrétaire de VIAVI Solutions Inc. (VIAV), a annoncé la vente de 9 927 actions ordinaires de l’émetteur effectuée le 25/09/2025. La vente a été réalisée dans le cadre d’un plan de négociation d’actions Rule 10b5-1 daté du 10 septembre 2024, et a été exécutée en plusieurs transactions à des prix compris entre $12,08 et $12,27, avec un prix moyen pondéré de vente de $12,17. Suite à la transaction reportée, la personne déclarant détenait de manière bénéficiaire 84 598 actions. Le Form 4 a été signé par l’avocat à tout faire Donna T. Rossi.
Kevin Christopher Siebert, Senior Vice President, General Counsel & Secretary von VIAVI Solutions Inc. (VIAV), meldete einen Verkauf von 9.927 Stammaktien des Emittenten am 25.09.2025. Der Verkauf erfolgte gemäß einem Rule 10b5-1-Aktienhandelplan datiert auf den 10. September 2024 und wurde in mehreren Transaktionen zu Preisen zwischen $12,08 und $12,27 durchgeführt, bei einem gewichteten durchschnittlichen Verkaufspreis von $12,17. Nach der gemeldeten Transaktion besaß die meldende Person vorteilhaft 84.598 Aktien. Das Formular 4 wurde von der gesetzlich befugten Vertreterin Donna T. Rossi unterzeichnet.
كيفن كريستوفر سيبرت، نائب رئيس الشركة التنفيذي المستشار العام وأمين سر شركة VIAVI Solutions Inc. (VIAV)، أبلغ عن بيع 9,927 سهم عادي من أسهم المصدر في 25/09/2025. تم البيع وفقاً لخطة تداول أسهم Rule 10b5-1 المؤرخة في 10 سبتمبر 2024، وتم التنفيذ في عدة صفقات بأسعار تتراوح بين $12,08 و$12,27، مع سعر بيع متوسط وزني قدره $12,17. وبعد المعاملة المذكورة، امتلك الشخص المبلغ عنه بشكل مفيد 84,598 سهم. وقد تم توقيع النموذج 4 من قبل الوكيل القانوني Donna T. Rossi.
Kevin Christopher Siebert,VIAVI Solutions Inc.(VIAV)的高级副总裁、通用顾问兼公司秘书,报告在
- Sale executed under a Rule 10b5-1 plan, indicating a pre-established, non-discretionary trading arrangement
- Complete price range disclosure ($12.08 to $12.27) with weighted average price reported ($12.17)
- Form 4 filed with attorney-in-fact signature, demonstrating procedural compliance
- Reporting person disposed of 9,927 shares, reducing beneficial ownership from prior levels to 84,598 shares
- Transaction reflects insider liquidity, which may be interpreted by some investors as a reduction in insider holdings
Insights
TL;DR: Insider sale under a pre-established plan; transaction is factual reporting, not a discretionary sale.
The Form 4 discloses a routine disposition of 9,927 shares by the company's SVP General Counsel executed under a Rule 10b5-1 plan. Because the sale was pre-planned and executed across multiple trades at prices between $12.08 and $12.27, the filing documents the mechanics and resulting beneficial ownership of 84,598 shares. This disclosure supplies transparency on insider liquidity but does not provide forward-looking operational or financial information about the company.
TL;DR: Disclosure aligns with governance best practices; sale executed under a documented 10b5-1 plan.
The submission shows compliance with Section 16 reporting requirements and cites a 10b5-1 trading plan dated September 10, 2024, which indicates the disposition was prearranged. The filing includes the requisite price range disclosure and attestation via attorney-in-fact signature. From a governance perspective, the document meets standard disclosure norms but contains no indication of unusual timing or material noncompliance.
Kevin Christopher Siebert, Senior Vice President, General Counsel e Segretario di VIAVI Solutions Inc. (VIAV), ha riportato una vendita di 9.927 azioni ordinarie dell'emittente in data 25/09/2025. La vendita è stata effettuata conformemente a un piano di negoziazione azionaria Rule 10b5-1 datato 10 settembre 2024 ed è stata eseguita in più operazioni a prezzi compresi tra $12,08 e $12,27, con un prezzo medio ponderato di vendita di $12,17. A seguito della transazione riportata, la persona che presenta il rapporto deteneva 84.598 azioni in modo benefit. Il Form 4 è stato firmato dall'avvocato-in-fatto Donna T. Rossi.
Kevin Christopher Siebert, vicepresidente senior y asesor jurídico general y Secretario de VIAVI Solutions Inc. (VIAV), informó la venta de 9.927 acciones ordinarias del emisor en 25/09/2025. La venta se realizó conforme a un plan de negociación de acciones Rule 10b5-1 con fecha del 10 de septiembre de 2024, y se ejecutó en múltiples operaciones a precios que oscilaron entre $12,08 y $12,27, con un precio medio ponderado de venta de $12,17. Tras la transacción reportada, la persona reportante poseía beneficiosamente 84.598 acciones. El Formulario 4 fue firmado por la apoderada Donna T. Rossi.
Kevin Christopher Siebert은 VIAVI Solutions Inc. (VIAV)의 SVP 일반 counsel 겸 비서로서 발행 회사의 보통주 9,927주를 2025-09-25에 매각했다고 보고했습니다. 매각은 Rule 10b5-1 주식 거래 계획에 따라 2024년 9월 10일에 date되었으며, $12.08에서 $12.27 사이의 가격으로 여러 차례 거래되었고, 가중평균 매각가 $12.17입니다. 보고된 거래 이후 보고서는 84,598주의 보유를 보고합니다. Form 4는 대리인 Donna T. Rossi가 서명했습니다.
Kevin Christopher Siebert, vice-président exécutif, conseil général et secrétaire de VIAVI Solutions Inc. (VIAV), a annoncé la vente de 9 927 actions ordinaires de l’émetteur effectuée le 25/09/2025. La vente a été réalisée dans le cadre d’un plan de négociation d’actions Rule 10b5-1 daté du 10 septembre 2024, et a été exécutée en plusieurs transactions à des prix compris entre $12,08 et $12,27, avec un prix moyen pondéré de vente de $12,17. Suite à la transaction reportée, la personne déclarant détenait de manière bénéficiaire 84 598 actions. Le Form 4 a été signé par l’avocat à tout faire Donna T. Rossi.
Kevin Christopher Siebert, Senior Vice President, General Counsel & Secretary von VIAVI Solutions Inc. (VIAV), meldete einen Verkauf von 9.927 Stammaktien des Emittenten am 25.09.2025. Der Verkauf erfolgte gemäß einem Rule 10b5-1-Aktienhandelplan datiert auf den 10. September 2024 und wurde in mehreren Transaktionen zu Preisen zwischen $12,08 und $12,27 durchgeführt, bei einem gewichteten durchschnittlichen Verkaufspreis von $12,17. Nach der gemeldeten Transaktion besaß die meldende Person vorteilhaft 84.598 Aktien. Das Formular 4 wurde von der gesetzlich befugten Vertreterin Donna T. Rossi unterzeichnet.